FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572854443> ?p ?o ?g. }

• W2572854443 abstract "Molecular breast imaging (MBI) performed with 99mTc sestamibi has been shown to be a valuable technique for the detection of breast cancer. Alternative radiotracers such as 99mTc maraciclatide may offer improved uptake in breast lesions. The purpose of this study was to compare relative performance of 99mTc sestamibi and 99mTc maraciclatide in patients with suspected breast cancer, using a high-resolution dedicated gamma camera for MBI. Women with breast lesions suspicious for malignancy were recruited to undergo two MBI examinations—one with 99mTc sestamibi and one with 99mTc maraciclatide. A radiologist interpreted MBI studies in a randomized, blinded fashion to assign an assessment score (1–5) and measured lesion size. Lesion-to-background (L/B) ratio was measured with region-of-interest analysis. Among 39 analyzable patients, 21 malignant tumors were identified in 21 patients. Eighteen of 21 tumors (86%) were seen on 99mTc sestamibi MBI and 19 of 21 (90%) were seen on 99mTc maraciclatide MBI (p = 1). Tumor extent measured with both radiopharmaceuticals correlated strongly with pathologic size (99mTc sestamibi, r = 0.84; 99mTc maraciclatide, r = 0.81). The L/B ratio in detected breast cancers was similar for the two radiopharmaceuticals: 1.55 ± 0.36 (mean ± S.D.) for 99mTc sestamibi and 1.62 ± 0.37 (mean ± S.D.) for 99mTc maraciclatide (p = 0.53). No correlation was found between the L/B ratio and molecular subtype for 99mTc sestamibi (r s = 0.12, p = 0.63) or 99mTc maraciclatide (r s = −0.12, p = 0.64). Of 20 benign lesions, 10 (50%) were seen on 99mTc sestamibi and 9 of 20 (45%) were seen on 99mTc maraciclatide images (p = 0.1). The average L/B ratio for benign lesions was 1.34 ±0.40 (mean ±S.D.) for 99mTc sestamibi and 1.41 ±0.52 (mean ±S.D.) for 99mTc maraciclatide (p = 0.75). Overall diagnostic performance was similar for both radiopharmaceuticals. AUC from ROC analysis was 0.83 for 99mTc sestamibi and 0.87 for 99mTc maraciclatide (p = 0.64). 99mTc maraciclatide offered comparable lesion uptake to 99mTc sestamibi, in both malignant and benign lesions. There was good correlation between lesion extent and uptake measured from both radiopharmaceuticals. 99mTc maraciclatide offered a marginal (but not significant) improvement in sensitivity over 99mTc sestamibi. Our findings did not support an association between the uptake of either radiopharmaceutical and tumor molecular subtype. ClinicalTrials.gov, NCT00888589" @default.
• W2572854443 created "2017-01-26" @default.
• W2572854443 creator A5029984891 @default.
• W2572854443 creator A5031722039 @default.
• W2572854443 creator A5033544737 @default.
• W2572854443 creator A5035722795 @default.
• W2572854443 creator A5036114249 @default.
• W2572854443 creator A5038107580 @default.
• W2572854443 creator A5061468680 @default.
• W2572854443 creator A5083575055 @default.
• W2572854443 date "2017-01-14" @default.
• W2572854443 modified "2023-10-15" @default.
• W2572854443 title "Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer" @default.
• W2572854443 cites W1535628679 @default.
• W2572854443 cites W1705216495 @default.
• W2572854443 cites W1909948732 @default.
• W2572854443 cites W1966980125 @default.
• W2572854443 cites W1976158114 @default.
• W2572854443 cites W1978139448 @default.
• W2572854443 cites W1986006134 @default.
• W2572854443 cites W1986641712 @default.
• W2572854443 cites W2008955556 @default.
• W2572854443 cites W2011157207 @default.
• W2572854443 cites W2023895653 @default.
• W2572854443 cites W2027666529 @default.
• W2572854443 cites W2029773366 @default.
• W2572854443 cites W2057620438 @default.
• W2572854443 cites W2063723874 @default.
• W2572854443 cites W2072228140 @default.
• W2572854443 cites W2082786039 @default.
• W2572854443 cites W2091492240 @default.
• W2572854443 cites W2100115519 @default.
• W2572854443 cites W2110369939 @default.
• W2572854443 cites W2112713388 @default.
• W2572854443 cites W2136750744 @default.
• W2572854443 cites W2137916135 @default.
• W2572854443 cites W2151162609 @default.
• W2572854443 cites W2166945186 @default.
• W2572854443 cites W2166998925 @default.
• W2572854443 cites W2268521229 @default.
• W2572854443 cites W2347016630 @default.
• W2572854443 cites W2400374665 @default.
• W2572854443 cites W2433116029 @default.
• W2572854443 cites W2539186936 @default.
• W2572854443 cites W3096743014 @default.
• W2572854443 cites W4229715865 @default.
• W2572854443 cites W4243708552 @default.
• W2572854443 doi "https://doi.org/10.1186/s13550-017-0255-6" @default.
• W2572854443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5237435" @default.
• W2572854443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28091980" @default.
• W2572854443 hasPublicationYear "2017" @default.
• W2572854443 type Work @default.
• W2572854443 sameAs 2572854443 @default.
• W2572854443 citedByCount "12" @default.
• W2572854443 countsByYear W25728544432017 @default.
• W2572854443 countsByYear W25728544432018 @default.
• W2572854443 countsByYear W25728544432020 @default.
• W2572854443 countsByYear W25728544432021 @default.
• W2572854443 countsByYear W25728544432022 @default.
• W2572854443 countsByYear W25728544432023 @default.
• W2572854443 crossrefType "journal-article" @default.
• W2572854443 hasAuthorship W2572854443A5029984891 @default.
• W2572854443 hasAuthorship W2572854443A5031722039 @default.
• W2572854443 hasAuthorship W2572854443A5033544737 @default.
• W2572854443 hasAuthorship W2572854443A5035722795 @default.
• W2572854443 hasAuthorship W2572854443A5036114249 @default.
• W2572854443 hasAuthorship W2572854443A5038107580 @default.
• W2572854443 hasAuthorship W2572854443A5061468680 @default.
• W2572854443 hasAuthorship W2572854443A5083575055 @default.
• W2572854443 hasBestOaLocation W25728544431 @default.
• W2572854443 hasConcept C121608353 @default.
• W2572854443 hasConcept C126322002 @default.
• W2572854443 hasConcept C126838900 @default.
• W2572854443 hasConcept C2776423551 @default.
• W2572854443 hasConcept C2777432617 @default.
• W2572854443 hasConcept C2779399171 @default.
• W2572854443 hasConcept C2779902710 @default.
• W2572854443 hasConcept C2780285475 @default.
• W2572854443 hasConcept C2780472235 @default.
• W2572854443 hasConcept C2910851616 @default.
• W2572854443 hasConcept C2989005 @default.
• W2572854443 hasConcept C522557706 @default.
• W2572854443 hasConcept C530470458 @default.
• W2572854443 hasConcept C71924100 @default.
• W2572854443 hasConceptScore W2572854443C121608353 @default.
• W2572854443 hasConceptScore W2572854443C126322002 @default.
• W2572854443 hasConceptScore W2572854443C126838900 @default.
• W2572854443 hasConceptScore W2572854443C2776423551 @default.
• W2572854443 hasConceptScore W2572854443C2777432617 @default.
• W2572854443 hasConceptScore W2572854443C2779399171 @default.
• W2572854443 hasConceptScore W2572854443C2779902710 @default.
• W2572854443 hasConceptScore W2572854443C2780285475 @default.
• W2572854443 hasConceptScore W2572854443C2780472235 @default.
• W2572854443 hasConceptScore W2572854443C2910851616 @default.
• W2572854443 hasConceptScore W2572854443C2989005 @default.
• W2572854443 hasConceptScore W2572854443C522557706 @default.
• W2572854443 hasConceptScore W2572854443C530470458 @default.
• W2572854443 hasConceptScore W2572854443C71924100 @default.
• W2572854443 hasFunder F4320309464 @default.
• W2572854443 hasFunder F4320332457 @default.

• next